Bioxcel Therapeuticsincis A Commercial Stage Biopharmaceutical Company Based In New Havenconnecticutfounded In 2017The Company Focuses On Developing Innovative Medicines Using Artificial Intelligenceparticularly In The Fields Of Neuroscience And Immuno Oncologybioxcel Aims To Enhance Drug Development By Efficiently Identifying Promising Drug Candidates To Address Unmet Medical Needs And Improve Patient Outcomes The Company Employs Ai And Machine Learning To Streamline The Drug Development Processre Innovating Existing Approved Drugs And Clinically Validated Candidatesbioxcel S Product Pipeline Includes Bxcl501An Adrenergic Agent For Neuropsychiatric And Neurodegenerative Diseasesbxcl701An Immuno Oncology Agent For Prostate And Pancreatic Cancersand Bxcl502Which Targets Symptoms From Neurological Disordersbioxcel Therapeutics Is Listed On The Nasdaq Under The Ticker Symbol Btai
